Abstract
Author(s): Karim Abdel Salam, Hatem el Sahar, Eman Mohamed Hassan, Mohammed AbdelRazeq*
Background: Postmenopausal Female Sexual Dysfunction (FSD) is a common issue impacting women's sexual health and quality of life. This study examines the effectiveness of autologous platelet-rich plasma (A-PRP) injections in treating FSD, aiming to assess improvements in sexual function and related distress. Methodology: A retrospective study was conducted at a private hospital from January 2020 to January 2022, involving 30 sexually active women aged 18 and older with diagnosed FSD. Participants received A-PRP injections in the vaginal and clitoral areas. The primary outcome measured was the Female Sexual Function Index (FSFI) total score, assessed before treatment and four months post-treatment. Secondary outcomes included the Female Sexual Distress Scale-Revised (FSD-R) scores. Informed consent and ethical approval were obtained. Results: Significant improvements were noted in FSD-R scores, with the total score decreasing from 19.33 ± 9.61 pretreatment to 10.63 ± 6.43 post-treatment (p < 0.001, 95% CI: 4.39, 13.01). FSFI scores also showed marked enhancement across all domains: desire (2.00 to 4.20, p < 0.001, CI: 1.80, 2.60), arousal (2.10 to 4.10, p < 0.001, CI: 1.56, 2.44), lubrication (3.00 to 4.80, p < 0.001, CI: 1.56, 2.04), orgasm (1.50 to 4.00, p < 0.001, CI: 1.94, 3.06), and satisfaction (2.00 to 4.80, p < 0.001, CI: 2.43, 3.17). The total FSFI score improved significantly from 16.50 ± 2.80 to 28.50 ± 2.50 (p < 0.001, CI: 10.60, 13.40). The pain domain showed no significant change (p = 0.085). Conclusion: A-PRP injections are a promising treatment for FSD, significantly improving sexual function and reducing distress in affected women. Continued research is essential to validate these findings and explore long-term outcomes.